AR063604A1 - Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo - Google Patents

Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo

Info

Publication number
AR063604A1
AR063604A1 ARP070104961A ARP070104961A AR063604A1 AR 063604 A1 AR063604 A1 AR 063604A1 AR P070104961 A ARP070104961 A AR P070104961A AR P070104961 A ARP070104961 A AR P070104961A AR 063604 A1 AR063604 A1 AR 063604A1
Authority
AR
Argentina
Prior art keywords
oxygen carrier
nitric oxide
attention
vasoactive
vasoactive oxygen
Prior art date
Application number
ARP070104961A
Other languages
English (en)
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063604(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of AR063604A1 publication Critical patent/AR063604A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
    • A61M16/1015—Preparation of respiratory gases or vapours with O2 features or with parameter measurement using a gas flush valve, e.g. oxygen flush valve
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A61M16/208—Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
    • A61M2016/102—Measuring a parameter of the content of the delivered gas
    • A61M2016/1035—Measuring a parameter of the content of the delivered gas the anaesthetic agent concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0266—Nitrogen (N)
    • A61M2202/0275—Nitric oxide [NO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y métodos para evitar o reducir la vasoconstricción en un mamífero luego de la administración de un portador de oxígeno vasoactivo (por ejemplo, un portador de oxígeno con base hemo como un portador de oxígeno en base a hemoglobina). Los métodos incluyen administrarle a un mamífero una composición que contiene un portador de oxígeno vasoactivo en combinación con uno o más de un compuesto liberador de óxido nítrico, un gas terapéutico que contiene óxido nítrico gaseoso, un inhibidor de la fosfodiesterasa y/o un sensibilizador de la guanilato ciclasa soluble. Reivindicación 87: Una composición farmacéutica que comprende (i) un inhibidor de la fosfodiesterasa, un sensibilizador de la guanilato ciclasa soluble, o un compuesto liberador de óxido nítrico; y (ii) un portador de oxígeno artificial.
ARP070104961A 2006-11-07 2007-11-07 Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo AR063604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86473406P 2006-11-07 2006-11-07

Publications (1)

Publication Number Publication Date
AR063604A1 true AR063604A1 (es) 2009-02-04

Family

ID=39430446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104961A AR063604A1 (es) 2006-11-07 2007-11-07 Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo

Country Status (10)

Country Link
US (1) US8887721B2 (es)
EP (2) EP2099463B1 (es)
JP (2) JP5697335B2 (es)
KR (2) KR101548692B1 (es)
CN (1) CN101573125B (es)
AR (1) AR063604A1 (es)
CL (1) CL2007003193A1 (es)
HK (1) HK1134455A1 (es)
TW (1) TWI474824B (es)
WO (1) WO2008063868A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US20130266668A1 (en) * 2010-12-01 2013-10-10 Virginia Commonwealth University Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
CN103429214B (zh) * 2011-03-09 2015-09-30 泰尔茂株式会社 氧运输体给予系统、氧运输体氧合装置及氧运输体用收容体
CA2840901C (en) * 2011-07-05 2020-12-15 New Health Sciences, Inc. A system for extended storage of red blood cells and methods of use
WO2013070592A1 (en) * 2011-11-07 2013-05-16 The General Hospital Corporation Treatment of red blood cells
JP6104513B2 (ja) * 2012-03-09 2017-03-29 エア・ウォーター株式会社 人工呼吸器
US20130274245A1 (en) * 2012-04-11 2013-10-17 Jan BLUMENSTEIN Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia
FR2990858B1 (fr) * 2012-05-24 2015-04-03 Air Liquide Sante Int Melange gazeux no/azote a teneur elevee en no pour traiter les detresses respiratoires hypoxemiantes severes
EP3967143A1 (en) 2013-02-28 2022-03-16 Hemanext Inc. Gas addition device for blood treatment and corresponding method
WO2015048766A1 (en) * 2013-09-30 2015-04-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona A home-based heliox system with carbon dioxide removal
WO2015100025A1 (en) * 2013-12-23 2015-07-02 Nitric Solutions Inc. Cystic fibrosis treatment comprising nitric oxide
US9381212B2 (en) * 2014-01-10 2016-07-05 Mallinckrodt Hospital Products IP Limited Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children
FR3017052B1 (fr) * 2014-01-31 2016-02-26 Air Liquide Sante Int Melange gazeux no/he a action bactericide
US10525226B2 (en) * 2014-05-14 2020-01-07 Mallinckrodt Hospital Products IP Limited Systems and methods for indicating lifetime of an NO2-to-NO reactor cartridge used to deliver NO for inhalation therapy to a patient
AU2016228993B2 (en) 2015-03-10 2022-02-10 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof
CA2983295C (en) 2015-04-23 2024-02-13 New Health Sciences, Inc. Anaerobic blood storage containers
CN107735095B (zh) 2015-05-18 2022-06-14 希玛奈克斯特股份有限公司 储存全血的方法及其组合物
CA3000210A1 (en) * 2015-10-01 2017-04-06 Mallinckrodt Hospital Products IP Limited Device and method for diffusing high concentration no with inhalation therapy gas
US10828436B2 (en) * 2016-04-05 2020-11-10 Vanderbilt University Administering the noble gas argon during cardiopulmonary resuscitation
MX2018014530A (es) 2016-05-27 2019-02-21 New Health Sciences Inc Almacenamiento anaerobico de sangre y metodo de inactivacion de patogenos.
MX2020010523A (es) 2017-02-27 2021-02-09 Third Pole Inc Sistemas y metodos para generar oxido nitrico.
AU2018322317B2 (en) 2017-08-25 2023-11-23 Mallinckrodt Pharmaceuticals Ireland Limited Methods to improve organ viability
CN113795291A (zh) * 2019-01-14 2021-12-14 背勒丰治疗公司 Pde-5抑制剂和吸入的一氧化氮的组合药物疗法
WO2020185674A1 (en) * 2019-03-08 2020-09-17 South Dakota Board Of Regents A vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing
WO2021258025A1 (en) * 2020-06-18 2021-12-23 Third Pole, Inc. Systems and methods for preventing and treating infections with nitric oxide
EP4405019A1 (en) 2021-09-23 2024-07-31 Third Pole, Inc. Systems and methods for delivering nitric oxide

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
DE122008000012I2 (de) * 1990-12-05 2012-04-12 Gen Hospital Corp Vorrichtung zum Behandeln einen Lungengefassverengung und von Asthma.
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5536241A (en) 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
DE59409834D1 (de) 1993-04-17 2001-09-27 Messer Griesheim Austria Ges M Gerät zur kontrollierten Zudosierung von NO zur Atemluft von Patienten
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
GB9320978D0 (en) 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
SE9303486L (sv) * 1993-10-22 1995-04-23 Siemens Elema Ab Metod vid bestämning av den funktionella residualkapaciteten för lungor samt en ventilatoranordning för bestämning av den funktionella residualkapaciteten
US5558083A (en) * 1993-11-22 1996-09-24 Ohmeda Inc. Nitric oxide delivery system
SE503876C2 (sv) * 1994-11-30 1996-09-23 Kjell Alving Detektion av inflammatoriska tillstånd i tarmkanalen genom att mäta kväveoxidhalten i ett prov taget ur tarmlumen
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5823180A (en) * 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
CN1208053C (zh) 1996-04-05 2005-06-29 综合医院公司 气体氧化氮在制备用于治疗血红蛋白病的冶疗气体中的应用
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6089229A (en) * 1998-05-26 2000-07-18 Datex-Ohmeda, Inc. High concentration no pulse delivery device
US6139506A (en) * 1999-01-29 2000-10-31 Instrumentarium Oy Method for measuring pulmonary functional residual capacity
US6237594B1 (en) * 1999-09-22 2001-05-29 Salter Labs Pneumatically-operated gas demand apparatus
US6894150B1 (en) * 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
WO2003000114A2 (en) 2001-06-21 2003-01-03 Beth Israel Deaconess Medical Center Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US6811778B2 (en) * 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
JP2006514621A (ja) * 2002-11-07 2006-05-11 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 出血性ショックの治療
WO2005007173A1 (en) * 2003-07-09 2005-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Use of nitrite salts for the treatment of cardiovascular conditions
WO2005077005A2 (en) 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
JP2008515825A (ja) * 2004-10-05 2008-05-15 バイエル・ヘルスケア・アクチェンゲゼルシャフト 気管支収縮および肺血管収縮の処置用のグアニル酸シクラーゼ刺激因子および一酸化窒素
US7530353B2 (en) * 2005-09-21 2009-05-12 The General Electric Company Apparatus and method for determining and displaying functional residual capacity data and related parameters of ventilated patients

Also Published As

Publication number Publication date
JP2015110642A (ja) 2015-06-18
KR20140088908A (ko) 2014-07-11
EP2099463A4 (en) 2010-04-21
TW200836752A (en) 2008-09-16
WO2008063868A3 (en) 2008-09-18
TWI474824B (zh) 2015-03-01
EP2099463B1 (en) 2014-07-16
US8887721B2 (en) 2014-11-18
KR101548692B1 (ko) 2015-09-01
EP2099463A2 (en) 2009-09-16
JP2010509353A (ja) 2010-03-25
HK1134455A1 (en) 2010-04-30
CL2007003193A1 (es) 2008-07-04
JP6095709B2 (ja) 2017-03-15
US20100051025A1 (en) 2010-03-04
WO2008063868A2 (en) 2008-05-29
JP5697335B2 (ja) 2015-04-08
KR20090087900A (ko) 2009-08-18
CN101573125A (zh) 2009-11-04
CN101573125B (zh) 2013-06-19
EP2514473A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
AR063604A1 (es) Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
AR067347A1 (es) Combinacion antihelmintica
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
DOP2010000387A (es) Compuestos pirazolicos 436
UY30440A1 (es) Nuevos compuestos
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
EA201491697A1 (ru) Составы агонистов гуанилатциклазы с и способы применения
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6351785A2 (es) Inhibidores de cinasa map p39
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
CR20120408A (es) ESTIMULADORES DE LA sGC O ACITVADORES DE LA sGC SOLOS Y EN COMBINACIÓN CON INHIBIDORES DE LA PDE5 PARA EL TRATAMIENTO DE LA FIBROSIS QUÍSTICA
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure